Neurocrine Biosciences, Inc. - Common Stock (NBIX)
Healthcare › Biological Products, (No Diagnostic Substances)
Price History
Feb 9, 2026 — Apr 1, 2026Investment Snapshot
- Trading 129% above Graham Number — above intrinsic value estimate
- Piotroski F-Score 4/9 — moderate financial health
- ROE of 14.0% — below-average profitability
- Revenue growing at 21% annually
Neurocrine Biosciences, Inc. - Common Stock (NBIX) is a Healthcare company operating in Biological Products, (No Diagnostic Substances), listed on the NASDAQ , with a market capitalisation of $13.2 billion . Key value metrics: P/E ratio 29.1, P/B ratio 4.06, Piotroski F-Score 4 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Neurocrine Biosciences, Inc. - Common Stock — Fundamental Analysis Summary
Neurocrine Biosciences, Inc. - Common Stock (NBIX) is currently trading 129% above its Graham Number of $57.48, suggesting the market price exceeds Benjamin Graham's intrinsic value estimate. The stock carries an elevated trailing P/E ratio of 29.1x.
On financial health, NBIX shows a moderate Piotroski F-Score of 4/9, and modest return on equity of 14.0% (sector average: -19.8%), and manageable leverage with a debt-to-equity ratio of 0.42.
StockPik's composite Value Score for NBIX is 59/100 — an above-average value rating. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
NBIX reports a high gross margin of 98.7% (sector average: 33.5%) and a strong operating margin of 22.1%.
NBIX shows revenue growing at 21% year-over-year, with earnings growing at 40%.